| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC3713 |
| Trial ID | NCT06198413 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | LX102 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD) |
| Year | 2023 |
| Country | China |
| Company sponsor | Innostellar Biotherapeutics Co.,Ltd |
| Other ID(s) | INNOSTELLAR-LX102A01-1 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||
|
|||||